TITLE

Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM

PUB. DATE
November 2011
SOURCE
Biomedical Market Newsletter;11/14/2011, Vol. 21, p282
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study led by North Carolina's Duke Clinical Research Institute (DCRI). The study is the first clinical trial of vorapaxar from Merck & Co. Inc. for the prevention of thrombosis and reduction of cardiovascular events. Comments from Kenneth W. Mahaffey, the author of the study, on the potential role of protease activated receptor 1 (PAR-1) vorapaxar are included.
ACCESSION #
69650251

 

Related Articles

  • Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar.  // Biomedical Market Newsletter;2/7/2012, Vol. 21, p1 

    The article reports on Merck & Co. Inc. announcing the results of the studies performed on Vorapaxar. Vorapaxar is an investigational oral Protease Activated Receptor 1 (PAR 1) thrombin receptor antagonist. It could be used for the prevention of thrombosis, reduction of cardiovascular diseases...

  • Zontivity.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, pA8 

    The article offers information about the Zontivity protease-activated receptor-1 (PAR-1) antagonist from Merck & Co. Inc.

  • SCH 79797, a selective PAR1 antagonist, protects against ischemia/reperfusion-induced arrhythmias in the rat hearts. MOHAMED, O. Y.; AL-MASRI, A. A.; EL ETER, E. A.; LATEEF, R. // European Review for Medical & Pharmacological Sciences;Nov2016, Vol. 20 Issue 22, p4796 

    OBJECTIVE: Thrombin is implicated in the genesis of arrhythmias and activation of thrombin receptors exacerbated ventricular arrhythmias following coronary artery ligation. The present study was designed to investigate the possible protective effect of the protease- activated receptor-1...

  • NEW PRODUCTS.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, pA10 

    The article offers brief information on two drugs including the Entyvio from the firm Takeda Pharmaceuticals and the Zontivity from the firm Merck & Co.

  • The Expression of the Thrombin Receptors PAR-3 and PAR-4 is Downregulated in Pancreatic Cancer Cell Lines. Rudroff, Claudia; Richard, Annette; Hilswicht, Sarah; Neugebauer, Edmund A. M. // Jurnalul de Chirurgie;2014, Vol. 10 Issue 1, p31 

    Background: Patients with pancreatic cancer frequently suffer from thrombosis as a consequence of excess thrombin generation. In addition to its role in the plasmatic coagulation cascade, thrombin induces numerous cellular effects by activating a unique group of G-protein-coupled receptors on...

  • Success of Vaccine Offers Promise of Cervical Cancer Prevention. Schultz, James // JNCI: Journal of the National Cancer Institute;1/15/2003, Vol. 95 Issue 2, p103 

    Cites the key findings of Merck and Company Inc.'s clinical trials on an investigational vaccine against the human papillomavirus type 16. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cervical cancer prevention.

  • EASL Roundup.  // BioWorld Today;4/20/2012, Vol. 23 Issue 77, p8 

    The article reports on the results from a Phase III open-label trial of two anemia management strategies conducted by Merck and Co. Inc. for patients in treatment with Victrelis (boceprevir) and Pegintron (peginterferonalfa-2b) and ribavirin for hepatitis C virus.

  • Clinic Roundup.  // BioWorld Today;12/19/2011, Vol. 22 Issue 243, p7 

    This section offers news briefs on clinical trials including the preliminary data obtained by Advaxis Inc. from a Phase II trial of ADXS-HPV, the trial initiated by Merck & Co. Inc. and Roche AG to test drug combinations for chronic hepatitis C virus genotype 1 infection, and enrollment...

  • Merck reports encouraging results from Phase IIb insomnia study.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p17 

    The article reports on the results of the Phase IIb clinical trial conducted by Merck & Co. Inc. which showed that dual orexin receptor antagonist is effective for treatment of primary insomnia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics